


Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells

April 1, 2019 – March 31, 2022

Highlights

- Will use Real-World Evidence to advance innovations in health care and health technology assessments.
- Aim 1: To examine the real-world uptake, safety, effectiveness and economic impact of the implementation of biosimilar bevacizumab in advanced colorectal cancer.
- Aim 2: To evaluate the real-world health outcomes and economic impact of CAR T-cell therapy.



About the project

New cancer therapies on the horizon provide great promise to cancer patients, however, these new technologies are often very expensive and resource intensive in a health system already strained. Two examples of these new therapies include biosimilars and Chimeric Antigen Receptor T-cell (CAR T-cell) therapy.

Biosimilars are biologic medical products that are equivalent, though not identical, to original biologics that are manufactured by different companies when original biologic patents expire. Biologics are often very expensive, with biosimilars promising substantial cost-savings once available.

While extremely promising for both pediatric leukemia and adult lymphoma populations in terms of efficacy, CAR T-cell therapy is very costly, and has significant toxicity and related resource needs associated with it.

Understanding the real-world uptake, budget impact, effectiveness, safety, and cost-effectiveness of these new technologies is critical for system planning, resource allocation, and especially, ensuring the best patient care possible. We will conduct real-world evaluations of biosimilar bevacizumab and CAR T-cell therapy, evaluating uptake, health outcomes, and economic impacts in the Ontario landscape. The evidence generated by these evaluations can then be used to make informed decisions regarding the real-world impact of these new technologies, and to help develop proper policies and guidelines to ensure the best evidence-based care for people with cancer.



Toronto

Ontario Health (Cancer Care Ontario)

Jaclyn Beca

Andrea Adamic

Tripat Gill

Rebecca Mercer

Elaine Meertens

Arthur Manzon

Sherrie Hertz

Sean Hopkins

Lisa Milgram

Jessica Arias

The Hospital for Sick Children

Dr. Petros Pechlivanoglou

Dr. Sumit Gupta

Princess Margaret Hospital

Dr. Christine Chen

Dr. Anca Prica

Dr. Danielle Rodin

Dr. David Hodgson

Sunnybrook (Odette Cancer Centre)

Dr. Lee Mozesohn

Dr. Matthew Cheung

Pan-Canadian Pharmaceutical Alliance

Sang Mi Lee

Waterloo

The University of Waterloo

Dr. William Wai Lun Wong

Ottawa

The Ottawa Hospital

Dr. Pierre Villeneuve

Dr. Chris Bredeson

Hamilton

Hamilton Health Sciences (Juravinski Cancer Centre)

Dr. Tom Kouroukis

Key Milestones

2019-2020

- Research ethics approval completed

2019-2020

- Budget Impact Analysis complete (Aim 1)

2020-2021

- Safety Analyses complete

2020-2021

- Effectiveness analyses complete

2020-2021

- Cost-effectiveness analysis complete (Aim 1)

Partners

Ontario Institute for Cancer Research - \$197,217

Ontario Health (Cancer Care Ontario) - \$40,540 (in-kind)

Canadian Centre for Applied Research in Cancer Control - \$11,160 (in-kind)

**The power to kill cancer lies within us.
Let's tell our bodies how.**